Replies to post #190053 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

The sleep products on the market now are all sedatives which have inherent danger.

Anavex 2-73 will probably prove to be safer than anything now on the market and the sleep provided allows healthy REM sleep which is blocked by sedatives.

[falconer66a]

Anavex 2-73 As A General Soporific

I would think more trials would be needed before it could be prescribed like an Ambien type product is.

I implied that if the only therapeutic positive to emerge from any of the three clinical trials were to be pronounced, facilitated sleep for those with central nervous system diseases, where sleep deprivation is a major problem, Anavex 2-73 might well gain approval for this use, alone.

Why would more trials, beyond the three in process now be needed, particularly the three-arm Alzheimer’s trial, with 450 patients? That trial will stack upon the now lengthy, extended results from the relative few Australians continuing to elect to take Anavex 2-73 long after their initial safety and tolerability trial ended.

In that trial, simply no incidences of debilitating or disqualifying adverse events; side effects. In every case, whether in extensive murine (lab rat) tests, or now with human clinical trials, Anavex 2-73 simply has produced no untoward side effects.

This was unexpected. Virtually every drug acting upon the brain or nerves has a host of serious side effects. Anavex 2-73 has none, because it works in nerves very differently from all the other neurotropic drugs. Take Ambien as an example. Check its side effects here: https://www.drugs.com/sfx/ambien-side-effects.html

Ambien is commonly prescribed for those suffering from sleep deprivation. Many taking the drug stop, because the side effects are worse than the sleep deprivation it supposedly treats. Anavex 2-73 has exhibited virtually none of these.

Think there might be a market for a safe, complete soporific drug? Here’s a report that loss of sleep causes a $411,00,000,000 loss in productivity each year in the US: http://fortune.com/2016/11/30/sleep-productivity-rand-corp-411-billion/